Wed.Aug 14, 2024

article thumbnail

CMS Issues Proposed Rule on the Medicare Part B and Part D Inflation Rebate Program; HPM Issues Detailed Summary

FDA Law Blog

By Alan M. Kirschenbaum & Michelle L. Butler & Faraz Siddiqui & Sophia R. Gaulkin — Enacted in 2022, the Inflation Reduction Act (IRA) amended the Medicare provisions of the Social Security Act to impose several discount requirements on pharmaceutical manufacturers. In addition to the widely publicized drug price negotiation program, the IRA established inflation rebate programs under Medicare Part B and Part D.

article thumbnail

Exploring the Use of Intranasal Dexmedetomidine for Anxiolysis and Minimal Sedation

PEMBlog

Intranasal dexmedetomidine is one of the latest sedative options that’s gaining traction, especially for non-painful procedures. Let’s take a closer look at what makes this medication so useful, particularly when given intranasally. What is Dexmedetomidine? Dexmedetomidine, often known by its brand name Precedex, is a fascinating medication. It’s a highly selective central alpha-2 agonist that’s able to induce a state of sedation that closely mimics natural sleep.